(Q51358946)

4 April 2018

title

Potential efficacy of imiquimod on immunity-related cytokines in murine skin in vivo and in human Langerhans cells in vitro. (English)

1 reference

4 April 2018

author name string

Xu Miao

1

1 reference

4 April 2018

Dan Luo

2

1 reference

4 April 2018

Wei Min

3

1 reference

4 April 2018

Xiangfei Lin

4

1 reference

4 April 2018

Daguang Wang

5

1 reference

4 April 2018

Yang Xu

6

1 reference

4 April 2018

Di Wu

7

1 reference

4 April 2018

publication date

20 February 2012

1 reference

4 April 2018

International Journal of Dermatology

published in

1 reference

4 April 2018

volume

51

1 reference

4 April 2018

issue

9

1 reference

4 April 2018

page(s)

1116-1122

1 reference

4 April 2018

Imiquimod for the treatment of genital warts: a quantitative systematic review

cites work

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Immunocryosurgery for basal cell carcinoma: results of a pilot, prospective, open-label study of cryosurgery during continued imiquimod application

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Treatment of primary limited cutaneous extramammary Paget's disease with topical imiquimod monotherapy: two case reports

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Cryosurgery during topical imiquimod: a successful combination modality for lentigo maligna

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Topical imiquimod in the treatment of metastatic melanoma to skin

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Keratinocytes and cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Cytokine modulation of keratinocyte cytokines

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Human keratinocytes contain mRNA indistinguishable from monocyte interleukin 1 alpha and beta mRNA. Keratinocyte epidermal cell-derived thymocyte-activating factor is identical to interleukin 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Regulation and role of interleukin 6 in wounded human epithelial keratinocytes

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Nickel and skin irritants up-regulate tumor necrosis factor-alpha mRNA in keratinocytes by different but potentially synergistic mechanisms

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Origin, homeostasis and function of Langerhans cells and other langerin-expressing dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Flow cytometric analysis of cytokine receptors on human Langerhans' cells. Changes observed after short-term culture

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Immunocytochemical detection of cytokines and chemokines in Langerhans cells and in vitro derived dendritic cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Early IL-2 Production by Mouse Dendritic Cells Is the Result of Microbial-Induced Priming

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Contribution of Langerhans cell-derived IL-18 to contact hypersensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Characterization of cryopreserved human Langerhans cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Postsurgical use of imiquimod 5% cream in the prevention of earlobe keloid recurrences: results of an open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Small anti-viral compounds activate immune cells via the TLR7 MyD88-dependent signaling pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Porcine TLR8 and TLR7 are both activated by a selective TLR7 ligand, imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Imiquimod and resiquimod as novel immunomodulators

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Immunomodulatory and pharmacologic properties of imiquimod

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

Extraction of human Langerhans cells: a method for isolation of epidermis-resident dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-4632.2011.05382.X

10.1111/J.1365-4632.2011.05382.X

21 January 2018

Identifiers

DOI

1 reference

4 April 2018

PubMed ID

22348684

1 reference

4 April 2018